We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets... Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers. Show more
Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in May 2024Initiation of a Phase 1 study to support a...
CHARLOTTESVILLE, Va., May 13, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic...
CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic...
CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic...
CHARLOTTESVILLE, Va., May 07, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel...
Presentation and poster include deeper data insights on sabirnetug safety profile, target engagement and fluid biomarker changesPresentation to be featured during AAN Emerging Science...
Lonza to manufacture Acumen’s monoclonal antibody, sabirnetug (ACU193), for clinical development and commercialization, if approvedSabirnetug is the first monoclonal antibody candidate to enter...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.42 | -14 | 3 | 3.07 | 2.44 | 439799 | 2.66392118 | CS |
4 | -1.02 | -28.3333333333 | 3.6 | 3.92 | 2.44 | 255005 | 3.0739894 | CS |
12 | -1.46 | -36.1386138614 | 4.04 | 4.43 | 2.44 | 272067 | 3.50527155 | CS |
26 | -0.26 | -9.15492957746 | 2.84 | 5.09 | 2.44 | 355721 | 3.58594621 | CS |
52 | -2.64 | -50.5747126437 | 5.22 | 11.3099 | 1.8101 | 575721 | 5.61103557 | CS |
156 | -22.49 | -89.7088153171 | 25.07 | 26.98 | 1.8101 | 412578 | 7.23257075 | CS |
260 | -22.49 | -89.7088153171 | 25.07 | 26.98 | 1.8101 | 412578 | 7.23257075 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions